JNJ
Johnson & JohnsonJohnson & Johnson is a pharmaceuticals name in the health care sector. Over the past year it returned +59.0%, against +19.6% over three months and +9.1% over one. It trades 19.1% above its 200-day average, so the longer trend is confirming recent strength. Annualized volatility of 18.5% is moderate by single-stock standards.
Its worst peak-to-trough decline over the year was -11.0%, and it has traded a median $1.8B a day — the figure that decides whether a position can actually be entered and exited at posted prices. Its daily moves correlate -0.15 with the S&P 500 proxy, so it has been moving substantially on its own.
How JNJ scores on all four profiles
Its standing on steadiness, defensiveness and rebound — plus the factor-by-factor breakdown behind each score, and its closest and least-correlated peers among 6 others in Pharmaceuticals.
Start a free 7-day trial| 1 day | +0.8% |
| 1 week | +4.8% |
| 1 month | +9.1% |
| 3 months | +19.6% |
| 6 months | +12.8% |
| 1 year | +59.0% |
| 12-1 momentum | +45.7% |
| Volatility (1y, annualized) | 18.5% |
| Max drawdown (1y) | -11.0% |
| Distance vs 200-day average | +19.1% |
| Return per unit of risk | 3.19 |
| Median daily dollar volume | $1.8B |
Get JNJ when it shows up in a ranking
Two editions a weekday, free — ranked lists built from this same data, on whatever the market is talking about.
Everything on this page is computed from daily adjusted closing prices. It contains no earnings, balance-sheet, guidance or ownership data, and it is not a valuation. Nothing here is tailored to your circumstances or a recommendation to buy or sell. Past performance does not predict future results.